Cybin Inc. (
NEO.CYBN,
OTC: CLXPF,
Forum) – a Toronto ON-based life sciences company initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and wellbeing – has announced the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for Mental Health.”
To hear the Audio Press Release, please visit
The NetworkNewsAudio News Podcast.
According to the company, there’s strong belief that different classes of psychedelics, such as ketamine, psilocybin, DMT and MDMA, can be developed for a wide range of unmet medical needs. These needs may include hard-to-treat disease and disorders such as anxiety, depression, addiction and post-traumatic stress, among others. In aggregate, mental health maladies affect more than 900 million people globally with direct and indirect economic costs of a staggering
$2.5 trillion. Today, therapeutics protocols are dominated by antipsychotic and antidepressant drugs, often in conjunction with some form of counseling therapy.
Full story
here.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the USA, UK and Ireland. The Company is focused on progressing ‘Psychedelics to Therapeutics’ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.
FULL DISCLOSURE: Cybin Inc. is a client of Stockhouse Publishing.